Any current/future new fundraising through debt or equity?

Hikal Limited has not explicitly mentioned any current or immediate plans for new fundraising through debt or equity in the call. Capital expenditure (capex) of INR149 crores during FY26 was financed through a balanced mix of internal accruals and debt. The company emphasizes a targeted capital allocation prioritizing high ROI projects aligned with long-term growth. The debt-to-equity ratio improved from 0.59 to 0.56 as of March 31, 2026, indicating prudent debt management. Growth initiatives and expansions are currently financed through internal accruals and existing debt facilities, ensuring

Any current/future capex/capital investment/strategic investment?

Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex. INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business. New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities. New pilot plant at U.S. FDA-approved Panoli facility to support growth. Planned HPAPI manufacturing facility in Pune targeted for FY '28. FY '26 capital expenditure of INR149 crores for debottleneck

Future growth expectations in sales/revenue/volumes?

Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. Animal Health business is projected to scale meaningfully over several years, supported by commercialization of existing programs and new CDMO opportunities. Pharma business volume growth is anticipated in FY '27, with quarter-on-quarter improvement expected, although no specific guidance will be given until Q1 FY '27 results. Crop business volume growth is positive but expected to be modest; growth will mainly come from Pharma, Animal Healt

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay. (Page 15) No specific guidance for FY '27 yet; management will provide clearer outlook after Q1 results due to current uncertainties like the global business environment and geopolitical issues. (Pages 18, 15) EBITDA margins improved to 20.3% in Q4 FY26, with FY26 margin at 12.9%, indicating operational improvement. (Page 5) Growth drivers include CDMO, Pharma, Animal Health, and Specialty Chemicals divisions; Crop business will show moderate growth. (Page 15) I

Current/ Expected Orderbook/ Pending Orders?

The order book for Hikal Limited remains intact despite recent challenges. There was a loss of business in Q4 due to FDA-related slowdowns, but recovery is expected in the next few quarters. CDMO segment continues to have long-term orders and engagements. Animal Health business is progressing well with validated products moving into the commercial phase. Encouraging inquiries and RFPs received from global customers, indicating a strong commercial pipeline. Customers have approved and reapproved facilities post-FDA issues, showing confidence and ongoing partnerships. Order book visibility is po

IN US

Sale is live|00:00:00left today

Hikal LtdQ1 FY26Pharmaceuticals & Biotechnology

Hikal Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact.
→Animal Health business is projected to scale meaningfully over several years, supported by commercialization of existing programs and new CDMO opportunities.
→Pharma business volume growth is anticipated in FY '27, with quarter-on-quarter improvement expected, although no specific guidance will be given until Q1 FY '27 results.
→Crop business volume growth is positive but expected to be modest; growth will mainly come from Pharma, Animal Health, and Specialty Chemicals divisions.
→The company aims for a top-line business of INR 500 crores plus in Animal Health within 4-5 years.
→Long-term growth target remains INR 3,500 to 4,000 crores by FY '30, though delayed by 2-3 years.
→Capital investments and strategic initiatives are expected to drive growth and improve margins going forward.

Margin guidance

Category 3

→Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay. (Page 15)
→No specific guidance for FY '27 yet; management will provide clearer outlook after Q1 results due to current uncertainties like the global business environment and geopolitical issues. (Pages 18, 15)
→EBITDA margins improved to 20.3% in Q4 FY26, with FY26 margin at 12.9%, indicating operational improvement. (Page 5)
→Growth drivers include CDMO, Pharma, Animal Health, and Specialty Chemicals divisions; Crop business will show moderate growth. (Page 15)
→Investments in manufacturing and compliance expected to support medium to long-term revenue and margin growth, targeting return on capital employed (ROCE) of 18-20%. (Pages 13, 15)
→FDA regulatory issues expected to resolve by end of FY '27, enabling normalization and revenue ramp-up. (Pages 13, 14)
→Management is confident of year-on-year growth, aiming to build INR 500 crore+ business in 4-5 years within Animal Health division. (Page 19)

3 more insights locked — sign up free to unlock

Fundraise plans

→Hikal Limited has not explicitly mentioned any current or immediate plans for new fundraising through debt or equity in the call.
→Capital expenditure (capex) of INR149 crores during FY26 was financed through a balanced mix of internal accruals and debt.
→The company emphasizes a targeted capital allocation prioritizing high ROI projects aligned with long-term growth.
→The debt-to-equity ratio improved from 0.59 to 0.56 as of March 31, 2026, indicating prudent debt management.
→Growth initiatives and expansions are currently financed through internal accruals and existing debt facilities, ensuring fiscal agility.
→No specific announcements regarding fresh equity or debt raising were indicated in the transcript.

Order book

→The order book for Hikal Limited remains intact despite recent challenges.
→There was a loss of business in Q4 due to FDA-related slowdowns, but recovery is expected in the next few quarters.
→CDMO segment continues to have long-term orders and engagements.
→Animal Health business is progressing well with validated products moving into the commercial phase.
→Encouraging inquiries and RFPs received from global customers, indicating a strong commercial pipeline.
→Customers have approved and reapproved facilities post-FDA issues, showing confidence and ongoing partnerships.
→Order book visibility is positive with gradual improvement in volumes and commercial traction across divisions.

Capex plans

Yes

→Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex.
→INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business.
→New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities.
→New pilot plant at U.S. FDA-approved Panoli facility to support growth.
→Planned HPAPI manufacturing facility in Pune targeted for FY '28.
→FY '26 capital expenditure of INR149 crores for debottlenecking, regulatory upgrades, and expanding CDMO capacities.
→Strategic investments made in the last 12-15 months becoming operational to support next phase of growth.
→Ongoing investments to upgrade quality systems and implement CAPA for regulatory compliance.
→Retooling of agrochemical multipurpose plant at Panoli into a pharmaceutical facility underway, with expected revenue generation starting next financial year.

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio